Recruitment
Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer
Helsinki, Finland, 16 June 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US. ValoTx’s CEO, Paul Higham, said, “I am delighted to welcome Dr Hemanshu Shah as our CBO. Hemanshu brings a wealth of business development experience from an impressive career spanning corporate development, strategy, and marketing roles at Transgene, Astellas, Johnson & Johnson
